ROIV Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

30.330

Open

29.490

VWAP

29.76

Vol

7.33M

Mkt Cap

21.17B

Low

29.365

Amount

218.20M

EV/EBITDA(TTM)

--

Total Shares

715.70M

EV

17.43B

EV/OCF(TTM)

--

P/S(TTM)

1.54K

Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.

Show More

Events Timeline

(ET)

2026-03-04

16:20:00

U.S. Service Sector Expansion Boosts Stocks

2026-03-04

12:00:00

Markets Rise Amid Geopolitical Headlines

2026-03-04

09:00:00

Futures Marginally Higher as Geopolitical Risks Rise

2026-03-04

06:50:00

Moderna Enters $950M Settlement Agreement with Arbutus

2026-03-03 (ET)

2026-03-03

16:30:00

Genevant and Arbutus Reach $2.25 Billion Settlement with Moderna

2026-03-03

07:20:00

Priovant Therapeutics' NDA for Brepocitinib Receives FDA Priority Review

News

NASDAQ.COM

03-06NASDAQ.COM

ROIV Options Contract Analysis and Investment Opportunities

NASDAQ.COM

03-05NASDAQ.COM

BlackBarn Capital Increases Warby Parker Stake by 2 Million Shares

Fool

BlackBarn Capital Increases Warby Parker Stake to 3 Million Shares

stocktwits

03-04stocktwits

Moderna-Arbutus-Genevant Patent Agreement: Wall Street Views It as Suboptimal, Yet Alleviates Pressure on MRNA Shares

Benzinga

Moderna Settles for $950 Million with Arbutus, Eyes Future Growth

stocktwits

03-03stocktwits

Moderna Settles for Up to $2.25 Billion with Arbutus and Genevant

8 Analyst Rating

Wall Street analysts forecast ROIV stock price to rise

7 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

22.00

Averages

27.63

High

33.00

Current: 0.000

Low

22.00

Averages

27.63

High

33.00

JPMorgan

Overweight

maintain

$31 -> $33

AI Analysis

2026-03-05

Reason

JPMorgan

Price Target

$31 -> $33

AI Analysis

2026-03-05

maintain

Overweight

Reason

JPMorgan raised the firm's price target on Roivant Sciences to $33 from $31 and keeps an Overweight rating on the shares. The firm updated the company's model to reflect the settlement with Moderna. JPMorgan sees the settlement as a "major overhang lift" for Roivant, saying investor attention now turns solely to the company's clinical readouts.

H.C. Wainwright

Buy

maintain

$33 -> $34

2026-03-04

Reason

H.C. Wainwright

Price Target

$33 -> $34

2026-03-04

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Roivant Sciences to $34 from $33 and keeps a Buy rating on the shares. The firm added the company's $2.25B in litigation proceeds to the model. Roivant announced that its subsidiary Genevant Sciences and Arbutus Biopharma have entered into a $2.25B global settlement with Moderna to resolve patent-infringement litigation related to Moderna's use of Genevant/Arbutus LNP delivery technology in its COVID-19 vaccine, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ROIV

Unlock Now

Valuation Metrics

The current forward P/E ratio for Roivant Sciences Ltd (ROIV.O) is -15.47, compared to its 5-year average forward P/E of -7.92. For a more detailed relative valuation and DCF analysis to assess Roivant Sciences Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-7.92

Current PE

-15.47

Overvalued PE

-3.49

Undervalued PE

-12.34

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-3.50

Current EV/EBITDA

-8.97

Overvalued EV/EBITDA

-0.98

Undervalued EV/EBITDA

-6.03

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

87.64

Current PS

195.15

Overvalued PS

177.14

Undervalued PS

-1.85

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

Stocks for short term gans

Intellectia · 19 candidates

Market Cap: >= 2.00BRsi Category: moderate, overboughtRelative Vol: >= 2Moving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $10.00

Ticker

Name

Market Cap$

Liberty Global Ltd

6.07B

Phibro Animal Health Corp

2.15B

Allegiant Travel Co

2.10B

Envista Holdings Corp

4.77B

XPO Inc

23.85B

Regal Rexnord Corp

14.06B

day trade most profitable right now

Intellectia · 24 candidates

Market Cap: >= 500.00MRegion: USPrice: $5.00 - $150.00Volume: >= 2,000,000Price Change Pct: >= $4.00Relative Vol: >= 2List Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

Pulse Biosciences Inc

1.33B

Liberty Global Ltd

6.26B

BILL Holdings Inc

4.32B

Sunopta Inc

756.00M

Lumen Technologies Inc

7.85B

Strategy Inc

40.50B

Whales Holding ROIV

PDT Partners, LLC

Two Seas Capital LP

Sofinnova Investment, Inc.

Perceptive Advisors LLC

Jefferies Financial Group Inc.

Rubric Capital Management LP

Trading Trends

People Also Watch

Frequently Asked Questions

What is Roivant Sciences Ltd (ROIV) stock price today?

The current price of ROIV is 29.58 USD — it has decreased -0.4

What is Roivant Sciences Ltd (ROIV)'s business?

Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.

What is the price predicton of ROIV Stock?

Wall Street analysts forecast ROIV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ROIV is27.63 USD with a low forecast of 22.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Roivant Sciences Ltd (ROIV)'s revenue for the last quarter?

Roivant Sciences Ltd revenue for the last quarter amounts to 2.00M USD, decreased -77.83

What is Roivant Sciences Ltd (ROIV)'s earnings per share (EPS) for the last quarter?

Roivant Sciences Ltd. EPS for the last quarter amounts to -0.38 USD, decreased -265.22

How many employees does Roivant Sciences Ltd (ROIV). have?

Roivant Sciences Ltd (ROIV) has 750 emplpoyees as of March 12 2026.

What is Roivant Sciences Ltd (ROIV) market cap?

Today ROIV has the market capitalization of 21.17B USD.